Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target
- 1 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 39 (24), 4711-4727
- https://doi.org/10.1038/s41388-020-1324-2
Abstract
Chordoma, a rare neoplasm derived from intraosseous notochordal remnants, is unresponsive to conventional chemotherapy and radiotherapy. Sonic Hedgehog (Shh) is a crucial fetal notochord-secreted morphogen that directs notochordal development. The aim of this study was to determine the functional roles and therapeutic potential of Shh-Gli1 signaling in chordomas. Tissue samples and clinical profiles were collected from 42 patients with chordoma. The chordoma cell lines U-CH1 and MUG-Chor1 were used for functional experiments. Shh-Gli1 signaling pathway genetic alterations were screened, and the functions of the identified novel variants were analyzed using in silico analyses, real-time quantitative PCR, and minigene assays. Ligand-dependent Shh-Gli1 signaling activation was assessed using single- and dual-label immunostaining, western blot analysis, and a Shh-responsive Gli-luciferase reporter assay. The small-molecule inhibitor vismodegib was used to target Shh-Gli1 signaling in vitro and in vivo. Overall, 44 genetic alterations were identified, including four novel variants (c.67_69dupCTG in SMO, c.-6_-4dupGGC and c.3306 + 83_3306 + 84insG in PTCH1, and c.183-67_183-66delinsA in SUFU). Shh, PTCH1, SMO, SUFU, and Gli1 were extensively expressed in chordomas, and higher Gli1 expression correlated with poorer prognosis. A luciferase reporter assay and dual-label immunostaining indicated the occurrence of juxtacrine ligand-dependent Shh-Gli1 signaling activation. Vismodegib significantly inhibited cell proliferation and induced apoptosis and G1/S cell cycle arrest. In vivo investigation demonstrated that vismodegib effectively inhibited chordoma xenograft growth. This current preclinical evidence elucidates the therapeutic potential of Shh-Gli1 signaling pathway targeting for chordoma treatment. Vismodegib may be a promising targeted agent, and further clinical trials are warranted.Funding Information
- National Natural Science Foundation of China (81641103, 81901202)
- China Postdoctoral Science Foundation (2018M630047)
This publication has 41 references indexed in Scilit:
- How to calculate sample size in animal studies?Journal of Pharmacology and Pharmacotherapeutics, 2013
- Common Genetic Variations in Patched1 (PTCH1) Gene and Risk of Hirschsprung Disease in the Han Chinese PopulationPLOS ONE, 2013
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaThe New England Journal of Medicine, 2012
- PTCH1 gene haplotype association with basal cell carcinoma after transplantationBritish Journal of Dermatology, 2010
- Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary functionNature Genetics, 2009
- Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesisProceedings of the National Academy of Sciences of the United States of America, 2009
- Identification of nucleus pulposus precursor cells and notochordal remnants in the mouse: Implications for disk degeneration and chordoma formationDevelopmental Dynamics, 2008
- Combination Treatment of Prostate Cancer Cell Lines with Bioactive Soy Isoflavones and Perifosine Causes Increased Growth Arrest and/or ApoptosisClinical Cancer Research, 2007
- Transcriptional Regulation of bcl-2 Mediated by the Sonic Hedgehog Signaling Pathway through gli-1Online Journal of Public Health Informatics, 2004
- Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumoursNature, 2003